Amarna Therapeutics has developed a groundbreaking non-immunogenic viral platform to deliver any transgene of choice into humans. It is advancing a pipeline of transformative, potentially curative gene therapies for a range of rare and prevalent diseases, including monogenetic indications, autoimmune diseases and chronic inflammation.
Latest news
Jan 11, 2022
Amarna Therapeutics and Redoxis receive EUREKA Eurostars grant to establish a screening platform for the advancement of a potential first-in-class gene therapy for ALS and other neurodegenerative diseases